Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma in the EU5 and a common indication for liver transplantation. The 2013-2015 EMA authorizations of Gilead\u2019s Sovaldi (sofosbuvir) and Harvoni (sofosbuvir\/ledipasvir), combined with Bristol-Myers Squibb\u2019s Daklinza (daclatasvir) and AbbVie\u2019s Viekirax +\/- Exviera (ombitasvir\/paritaprevir\/ritonavir +\/- dasabuvir), have ushered in the era of IFN-free therapy for chronic HCV and completely reshaped the HCV therapeutic market. Recent EMA approvals of Gilead\u2019s Epclusa (sofosbuvir\/velpatasvir) and Merck & Co\u2019s Zepatier (elbasvir\/grazoprevir) provide additional IFN-free options for EU5 HCV patients. Taken together, currently approved regimens provide efficacious IFN-free options for most HCV genotypes in the EU5. This research focuses on current and anticipated use of HCV regimens, including IFN-free and remaining IFN-based regimens, by capturing patient-share data, current prescribing trends, and anticipated changes in prescribing and treatment. We also evaluate physician-perceived drivers and obstacles to the uptake of key brands.<\/p>\n
Questions Answered in This Report:<\/strong><\/p>\n What factors influence physicians\u2019 treatment and management of chronic HCV infections?<\/p>\n What are the major drug attributes driving physicians to prescribe certain brands?<\/p>\n What obstacles prevent physician prescribing of key HCV therapies?<\/p>\n How do physicians anticipate their prescribing of different therapies to change in the next six months?<\/p>\n Scope:<\/strong><\/p>\n Markets covered:<\/strong> France, Germany, Italy, Spain, and United Kingdom<\/p>\n Methodology: <\/strong> Survey of 89 gastroenterologists and 162 hepatologists; approximately 50 respondents per EU5 country<\/p>\n Key drugs covered: <\/strong>Incivo, Victrelis, Sovaldi, Olysio, Daklinza, Harvoni, Viekirax + Exviera, Zepatier, Epclusa, glecaprevir\/pibrentasvir, sofosbuvir\/velpatasvir\/voxilaprevir<\/p>\n Key<\/strong> companies mentioned:<\/strong> AbbVie, Bristol-Myers Squibb, Gilead, Merck & Co., Janssen, Johnson & Johnson, Roche<\/p>\n","protected":false},"template":"","class_list":["post-390942","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hepatitis-c-virus","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390942","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390942\/revisions"}],"predecessor-version":[{"id":576827,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390942\/revisions\/576827"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390942"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}